References
- DingJWongTYCurrent epidemiology of diabetic retinopathy and diabetic macular edemaCurr Diab Rep201212434635422585044
- BosciaFCurrent approaches to the management of diabetic retinopathy and diabetic macular oedemaDrugs201070162171220020964459
- CheungNMitchellPWongTYDiabetic retinopathyLancet2010376973512413620580421
- CiullaTAAmadorAGZinmanBDiabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapiesDiabetes Care20032692653266412941734
- DavidovEBreitscheidelLClouthJReipsMHappichMDiabetic retinopathy and health-related quality of lifeGraefes Arch Clin Exp Ophthalmol2009247226727218925408
- LamoureuxELTaiESThumbooJImpact of diabetic retinopathy on vision-specific functionOphthalmology2010117475776520122736
- MatzaLSRousculpMDMalleyKBoyeKSOglesbyAThe longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathyHealth Qual Life Outcomes200869518992161
- ChenELoomanMLaouriMBurden of illness of diabetic macular edema: literature reviewCurr Med Res Opin20102671587159720429823
- DelcourtCSivaprasadSBandelloFPrevalence of diabetic macular edema (DME) in Europe: the Pan European Prevalence Assessment of DME with Visual Impairment (PREVAIL) study Submitted
- ShawJESicreeRAZimmetPZGlobal estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract201087141419896746
- BhagatNGrigorianRATutelaAZarbinMADiabetic macular edema: pathogenesis and treatmentSurv Ophthalmol200954113219171208
- KlaassenIVan NoordenCJSchlingemannROMolecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditionsProg Retin Eye Res201334194823416119
- ZhangXBaoSHamblyBDGilliesMCVascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathyInt J Biochem Cell Biol200941122368237119646547
- NguyenQDBrownDMMarcusDMRISE RIDE Research GroupRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology2012119478980122330964
- BrownDMNguyenQDMarcusDMRISE RIDE Research GroupLong-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDEOphthalmology2013120102013202223706949
- MitchellPBandelloFSchmidt-ErfurthURESTORE Study GroupThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology2011118461562521459215
- European Medicines AgencyAssessment Report for Lucentis (Ranibizumab). EMA/13901/20112010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000715/WC500101009.pdfAccessed October 7, 2014
- European Medicines AgencyAssessment Report for Eylea (Aflibercept). EMA/430291/20142014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002392/WC500172846.pdfAccessed October 7, 2014
- KorobelnikJFDoDVSchmidt-ErfurthUIntravitreal aflibercept for diabetic macular edemaOphthalmology2014121112247225425012934
- MitchellPAnnemansLGallagherMCost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trialBr J Ophthalmol201296568869322399690
- National Institute for Health and Care ExcellenceRanibizumab for Treating Diabetic Macular Oedema (Rapid Review of Technology Appraisal Guidance 237) [TA274]2013 Available from: http://www.nice.org.uk/guidance/ta274Accessed October 7, 2014
- KleinRKleinBEMossSEDeMetsDLKaufmanIVossPSPrevalence of diabetes mellitus in southern WisconsinAm J Epidemiol1984119154616691336
- KleinRKleinBEMossSEDavisMDDeMetsDLThe Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 yearsArch Ophthalmol198410245205266367724
- RegnierSMalcolmWAllenFWrightJBezlyakVEfficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysisPLoS One201497e10230925029255
- PruenteCGroupRSEfficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN studyInvest Ophthalmol Vis Sci201455 E-Abstract 1700
- BresslerNMChangTSSuñerIJMARINA and ANCHOR Research GroupsVision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOROphthalmology20101174747.e756.e20189654
- Czoski-MurrayCCarltonJBrazierJYoungTPapoNLKangHKValuing condition-specific health states using simulation contact lensesValue Health200912579379919490557
- National Institute for Health and Care ExcellenceAflibercept Solution for Injection for Treating Wet Age-Related Macular Degeneration [TA294]2013 Available from: http://www.nice.org.uk/guidance/ta294Accessed October 7, 2014
- ElmanMJQinHAielloLPBeckRWIntravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial resultsOphthalmology2012119112312231822999634
- European Medicines AgencyLucentis: EPAR – Product Information2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdfAccessed March 4, 2015
- CampochiaroPASophieRPearlmanJRETAIN Study GroupLong-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN studyOphthalmology2014121120921924112944
- ClaxtonKMartinSSoaresMMethods for the Estimation of the NICE Cost Effectiveness ThresholdNew YorkUniversity of York, Centre for Health Economics2013
- BriggsAClaxtonKSculpherMDecision Modelling for Health Economic EvaluationOxfordOxford University Press2006
- JusufbegovicDMugavinMOSchaalSEvolution of controlling diabetic retinopathy: changing trends in the management of diabetic macular edema at a single institution over the past decadeRetina Epub1142015
- PetrellaRJBlouinJDaviesBBarbeauMPrevalence, demographics, and treatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohortJ Ophthalmol2012201215916723304447
- LangGEBertaAEldemBMRESTORE Extension Study GroupTwo-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension studyOphthalmology2013120102004201223725735
- SchmidMKBachmannLMFäsLKesselsAGJobOMThielMAEfficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysisBr J Ophthalmol201599214114625271911
- European Medicines AgencyEylea: EPAR – Product Information2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdfAccessed March 5, 2014
- Early Treatment Diabetic Retinopathy Study Research GroupTreatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2Ophthalmology19879477617743658348
- Schmidt-ErfurthULangGEHolzFGRESTORE Extension Study GroupThree-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension studyOphthalmology201412151045105324491642
- Efficacy and safety of ranibizumab monotherapy or combined with laser versus laser monotherapy in diabetic macular edema: the RESPOND studyCan J Ophthalmol2015In press
- BakshiNKUpdate on the VIVID-DME and VISTA-DME trialsOphthalmol Sci Update2014 Available from: http://www.ophthalmologyupdate.ca/crus/230-015%206-pages%20English.pdfAccessed October 15, 2014
- UK Department of Health2011–2012 NHS Reference Costs2014 Available from: https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012Accessed October 7, 2014
- ShyangdanDCumminsELoisNRoylePWaughNDexamethasone Implants in the Treatment of Macular Oedema Due to Retinal Vein Occlusion: A Single Technology AppraisalAberdeen Health Technology Assessment Group 20102014 Available from: http://www.nice.org.uk/nicemedia/live/13037/52883/52883.pdfAccessed October 7, 2014
- Hospital and Community Health ServicesHCHS Pay and Prices Series 2010–20112014 Available from: http://www.info.doh.gov.uk/doh/finman.nsf/af3d43e36a4c8f8500256722005b77f8/276315c0677bf5478025796b00418a4d?OpenDocumentAccessed October 16, 2014
- Personal Social Services Research UnitUnit Costs of Health and Social Care 20112014 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2011/Accessed October 7, 2014
- Personal Social Services Research UnitUnit Costs of Health and Social Care 20032014 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2003/Accessed October 7, 2014
- McCronePDhanasiriSPatelAKnappMLawton-SmithSPaying the Price (2008): the Cost of Mental Health Care in England to 20262014 Available from: http://www.kingsfund.org.uk/publications/paying-priceAccessed October 7, 2014
- ApplebyJPoteliakhoffEShahKDevlinNUsing patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitalsJ R Soc Med2013106832333123759892